How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,932 results for

Follicle Stimulating Hormone

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease. (Full text)

Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease. Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder characterized by the progressive development of renal and hepatic cysts. Follicle-stimulating hormone (FSH) has been demonstrated to be a trophic factor for biliary cells in normal rats and experimental cholestasis induced by bile duct ligation (BDL).To assess the effect of FSH on cholangiocyte (...) ) with or without transient silencing of the FSH gene.Follicle-stimulating hormone is linked to the active proliferation of the cystic wall and to the localization of p-ERK and c-myc. This hormone sustains the biliary growth by activation of the cAMP/ERK signalling pathway.These results showed that FSH has an important function in cystic growth acting on the cAMP pathway, demonstrating that it provides a target for medical therapy of hepatic cysts during ADPKD.© 2013 John Wiley & Sons A/S. Published by John

2013 Liver International PubMed abstract

262. Follicle-stimulating hormone enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. (Full text)

Follicle-stimulating hormone enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Recent studies have suggested that FSH plays an important role in ovarian epithelial carcinogenesis. We demonstrated that FSH stimulates the proliferation and invasion of ovarian cancer cells, inhibits apoptosis and facilitates neovascularisation. Our previous work has shown that transient receptor potential channel C3 (TRPC3) contributes to the progression (...) of human ovarian cancer. In this study, we further investigated the interaction between FSH and TRPC3. We found that FSH stimulation enhanced the expression of TRPC3 at both the mRNA and protein levels. siRNA-mediated silencing of TRPC3 expression inhibited the ability of FSH to stimulate proliferation and blocked apoptosis in ovarian cancer cell lines. FSH stimulation was associated with the up-regulation of TRPC3, while also facilitating the influx of Ca(2)(+) after treatment with a TRPC-specific

2013 Endocrine-Related Cancer PubMed abstract

263. Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome. (Full text)

Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome. Women with anovulatory polycystic ovary syndrome (PCOS) are generally insulin-resistant and as a consequence are often treated with the biguanide metformin. Results with metformin have, however, been variable with some studies demonstrating induction of regular cycles and an increase in ovulation, whereas others do not. Hence more understanding is needed regarding (...) the mechanism of metformin's actions in ovarian granulosa cells especially in light of previous demonstrations of direct actions.The aim of this study was to investigate metformin's interaction with the FSH/cAMP/protein kinase A pathway, which is the primary signaling pathway controlling CYP19A1 (aromatase) expression in the ovary.The effect of metformin on FSH and forskolin-stimulated aromatase expression in human granulosa cells was measured by quantitative real-time PCR. Activity was assessed after

2013 Journal of Clinical Endocrinology and Metabolism PubMed abstract

264. Antimüllerian as predictor of reproductive outcome in subfertile women with elevated basal follicle-stimulating hormone levels: a follow-up study. (Abstract)

Antimüllerian as predictor of reproductive outcome in subfertile women with elevated basal follicle-stimulating hormone levels: a follow-up study. To investigate the role of serum antimüllerian hormone (AMH) as a predictor of live birth and reproductive stage in subfertile women with elevated basal FSH levels.A prospective observational cohort study conducted between February 2005 and June 2009.Tertiary fertility center.Subfertile women with [1] a regular menstrual cycle (mean cycle length 25

2013 Fertility and Sterility

265. Trial of Recombinant Follicle Stimulating Hormone (rFSH) Pre-treatment for GnRH-induced Fertility in Patients with Congenital Hypogonadotropic Hypogonadism. (Full text)

Trial of Recombinant Follicle Stimulating Hormone (rFSH) Pre-treatment for GnRH-induced Fertility in Patients with Congenital Hypogonadotropic Hypogonadism. The optimal strategy for inducing fertility in men with congenital hypogonadotropic hypogonadism (CHH) is equivocal. Albeit a biologically plausible approach, pretreatment with recombinant FSH (rFSH) before GnRH/human chorionic gonadotropin administration has not been sufficiently assessed. The objective of the study was to test (...) this method.This was a randomized, open-label treatment protocol at an academic medical center.GnRH-deficient men (CHH) with prepubertal testes (<4 mL), no cryptorchidism, and no prior gonadotropin therapy were randomly assigned to either 24 months of pulsatile GnRH therapy alone (inducing endogenous LH and FSH release) or 4 months of rFSH pretreatment followed by 24 months of GnRH therapy. Patients underwent serial testicular biopsies, ultrasound assessments of testicular volume, serum hormone measurements

2013 The Journal of clinical endocrinology and metabolism Controlled trial quality: uncertain PubMed abstract

266. Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR) (Full text)

Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR) Anti-Her-2 treatment is successfully administered to Her-2 overexpressing breast cancer patients and significantly implicates upon their survival. Building on these promising results, anti-Her-2 treatment protocols were tested as an option for epithelial ovarian cancer (EOC) as well. However Her-2 signalling is known to be modulated by G-protein coupled

2013 Journal of ovarian research PubMed abstract

267. The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies. (Full text)

The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies. Follicle-stimulating hormone (FSH) is a central hormone in mammalian reproductive biology. The FSH receptor (FSHR), which was previously believed to be expressed primarily in the ovary and testis, was recently found to be expressed in the tumor blood vessels of many solid tumor types, including prostate adenocarcinoma, urothelial carcinoma, and renal cell carcinoma. While the biologic significance of FSHR

2013 Urologic oncology PubMed abstract

268. Superoxide dismutase-loaded biodegradable nanoparticles targeted with a follicle-stimulating hormone peptide protect Sertoli cells from oxidative stress. (Abstract)

Superoxide dismutase-loaded biodegradable nanoparticles targeted with a follicle-stimulating hormone peptide protect Sertoli cells from oxidative stress. To evaluate targeted superoxide dismutase (SOD)-loaded biodegradable nanoparticles' (NPs) ability to protect Sertoli cells from hydrogen peroxide (H2O2)-induced oxidative stress.Cell culture controlled experimental study.Research laboratory.Mouse testis Sertoli cells (TM4).Sertoli cells were exposed to 0-200 μg/mL plain media, unconjugated NPs

2013 Fertility and Sterility

269. Alpha-melanocyte-stimulating hormone - a protective peptide against chemotherapy-induced hair follicle damage? (Abstract)

Alpha-melanocyte-stimulating hormone - a protective peptide against chemotherapy-induced hair follicle damage? Effective, safe and well-tolerated therapeutic and/or preventive regimens for chemotherapy-induced alopecia (CIA) still remain to be developed. Because α-melanocyte-stimulating hormone (α-MSH) exerts a number of cytoprotective effects and is well tolerated, we hypothesized that it may be a candidate CIA-protective agent.To explore, using a human in vitro model for chemotherapy-induced (...) hair follicle (HF) dystrophy that employs the key cyclophosphamide metabolite (4-hydroperoxy-cyclophosphamide, 4-HC), whether α-MSH protects from 4-HC-induced HF dystrophy.Microdissected human scalp HFs from four individuals were treated with 4-HC, α-MSH and 4-HC plus α-MSH. Changes in HF cycling, melanin distribution and hair matrix keratinocyte proliferation/apoptosis were examined by quantitative (immune-) morphometry. Expression of the cytoprotective enzyme haem oxygenase-1 (HO-1

2013 British Journal of Dermatology

270. Hypothalamic-Pituitary-Thyroid Axis Hormones Stimulate Mitochondrial Function and Biogenesis in Human Hair Follicles. (Full text)

Hypothalamic-Pituitary-Thyroid Axis Hormones Stimulate Mitochondrial Function and Biogenesis in Human Hair Follicles. Thyroid hormones regulate mitochondrial function. As other hypothalamic-pituitary-thyroid (HPT) axis hormones, i.e., thyrotropin-releasing hormone (TRH) and thyrotropin (TSH), are expressed in human hair follicles (HFs) and regulate mitochondrial function in human epidermis, we investigated in organ-cultured human scalp HFs whether TRH (30 nM), TSH (10 mU ml(-1)), thyroxine (T4 (...) ) (100 nM), and triiodothyronine (T3) (100 pM) alter intrafollicular mitochondrial energy metabolism. All HPT-axis members increased gene and protein expression of mitochondrial-encoded subunit 1 of cytochrome c oxidase (MTCO1), a subunit of respiratory chain complex IV, mitochondrial transcription factor A (TFAM), and Porin. All hormones also stimulated intrafollicular complex I/IV activity and mitochondrial biogenesis. The TSH effects on MTCO1, TFAM, and porin could be abolished by K1-70, a TSH

2013 Journal of Investigative Dermatology PubMed abstract

271. Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. (Full text)

Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. The Follicle Stimulating Hormone receptor (FSHR) is expressed by the vascular endothelium in a wide range of human tumors. It was not determined however if FSHR is present in metastases which are responsible for the terminal illness.We used immunohistochemistry based on a highly FSHR-specific monoclonal antibody to detect FSHR in cancer metastases from 6 major tumor types (lung, breast, prostate

2013 BMC Cancer PubMed abstract

272. Follicular characteristics and luteal development after follicle-stimulating hormone induced multiple ovulations in heifers. (Full text)

Follicular characteristics and luteal development after follicle-stimulating hormone induced multiple ovulations in heifers. A protocol based on small doses of FSH was examined for the induction of double or triple (multiple) ovulations in cattle. Ovulation rate, follicular characteristics, and luteal responses were determined. In Exp. 1, three groups of estrous-synchronized, cyclic Holstein heifers were treated once daily, on d 3 to 6 of the cycle, with a FSH product (Folltropin-V): large FSH (...) dose (total of 150 mg; n=18), medium FSH dose (total of 130 mg, n=12), and small FSH dose (total of 80 mg; n=7). Controls received saline (n=6). Prostaglandin F(2α) was injected on d 6, ultrasound-guided aspiration of surplus follicles (if needed) was performed on d 7, and GnRH was injected on d 8 to induce ovulation. The large FSH dose induced growth of more (2.6±0.3, P<0.05) large follicles than controls on d 8; medium and small FSH doses insufficiently stimulated growth of <2 large follicles

2013 Journal of animal science Controlled trial quality: uncertain PubMed abstract

273. Follicle-stimulating hormone stimulates estradiol-17beta synthesis in cultured Sertoli cells. (Full text)

Follicle-stimulating hormone stimulates estradiol-17beta synthesis in cultured Sertoli cells. Sertoli cells isolated from testes of 20-day-old rats and maintained in primary culture synthesized estradiol-17beta [1,3,5(10)-estratriene-3,17beta-diol] (measured by specific radioimmunoassay) when testosterone (17beta-hydroxy-4-androsten-3-one) 0.5 muM, was added to the culture medium. No detectable estradiol synthesis occurred when cells were incubated in medium containing pregnenolone (3beta (...) -hydroxypregn-5-en-20-one), 0.5 muM, or containing no added steroid substrate. Follicle-stimulating hormone (FSH) (NIH-FSH-S10, 5 mug/ml) stimulated estradiol synthesis 12- to 80-fold when added to medium containing testosterone, but not when added to medium containing pregnenolone or no exogenous steroid substrate. A highly purified FSH preparation, with FSH potency 50 times that of the NIH-FSH, caused a similar stimulation at a concentration of 0.25 mug/ml of medium, whereas luteinizing hormone (NIH-LH

1975 Proceedings of the National Academy of Sciences of the United States of America PubMed abstract

274. Influence of artificially induced light pollution on the hormone system of two common fish species, perch and roach, in a rural habitat (Full text)

-ketotestosterone) as well as mRNA expression of gonadotropins (luteinizing hormone, follicle stimulating hormone) was reduced in both fish species. We conclude that ALAN can disturb biological rhythms in fish in urban waters. However, impacts on melatonin rhythm might have been blurred by individual differences, sampling methods and moonlight. The effect of ALAN on biomarkers of reproduction suggests a photo-labile period around the onset of gonadogenesis, including the experimental period (August). Light (...) Influence of artificially induced light pollution on the hormone system of two common fish species, perch and roach, in a rural habitat Almost all life on earth has adapted to natural cycles of light and dark by evolving circadian and circannual rhythms to synchronize behavioural and physiological processes with the environment. Artificial light at night (ALAN) is suspected to interfere with these rhythms. In this study we examined the influence of ALAN on nocturnal melatonin and sex steroid

2018 Conservation physiology PubMed abstract

275. Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in the Urine of Prepubertal Children (Full text)

Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in the Urine of Prepubertal Children Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) have been measured by specific bioassays in pooled urine samples from prepubertal children, aged 2-6 yr, and from male adults. For children the mean urinary excretion of FSH was 2.2 U 2nd International Reference Preparation (2nd IRP) per liter and the mean urinary excretion of LH was 0.44 U 2nd IRP per liter. For adults the mean FSH

1967 Journal of Clinical Investigation PubMed abstract

276. Antibody to human follicle-stimulating hormone: cross-reactivity with three other hormones (Full text)

Antibody to human follicle-stimulating hormone: cross-reactivity with three other hormones Antibodies directed against human follicle-stimulating hormone (FSH) were demonstrated in rabbit serum by neutralization of biological activity. Antibodies that bound FSH-(131)I were produced in rabbits and guinea pigs by repeated injections of FSH. By (131)I immunochemical methods, we found that at least 90% of the FSH-(131)I-binding antibody failed to distinguish the four human glycoprotein hormones (...) : FSH, luteinizing hormone, chorionic gonadotropin, and thyrotropin, purified as well as endogenous hormone in plasma. Neither growth hormone, adrenocorticotropin, nor a variety of glycoproteins or animal plasmas were able to react with these antibodies.

1968 Journal of Clinical Investigation PubMed abstract

277. Hormonal responses and clinical outcome are the same with three doses of gonadotropin-releasing hormone agonist used in the short stimulation protocol. (Full text)

Hormonal responses and clinical outcome are the same with three doses of gonadotropin-releasing hormone agonist used in the short stimulation protocol. The aim of this study was to compare 3 different doses of GnRH-a in a short protocol on ICSI outcome.91 ovulatory patients were randomly assigned to three groups; group A (N=34), group B (N=34) and group C (N=23). All started treatment with urinary gonadotropins, 2 ampoules per day and GnRH-a (Triptorelin) on the first day of the menstrual (...) period and continued till the day of (hCG) administration. The daily dose of Triptorelin was 0.1 mg, 50 µg, and 25 µg in groups A, B and C respectively.Stimulation requirements, days of stimulation and total ampoules of gonadotropins did not differ between the three groups. The mean number of follicles aspirated and the mean number of Metaphase 2 oocytes retrieved were similar in the three groups. Fertilization and cleavage rates were similar in the three groups. The mean number of embryos available

2016 JBRA assisted reproduction Controlled trial quality: uncertain PubMed abstract

278. Phthalate exposure and reproductive hormones and sex-hormone binding globulin before puberty - Phthalate contaminated-foodstuff episode in Taiwan. (Full text)

children were included in the statistical analyses. After adjustment for age and birth weight, girls with above median levels of urinary mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, and sum of mono-(2-ethylhexyl) phthalate concentrations had higher odds of above median follicle-stimulating hormone concentrations. Girls with above median estimated average daily DEHP exposures following the contamination episode also had higher odds of sex hormone-binding globulin above (...) Phthalate exposure and reproductive hormones and sex-hormone binding globulin before puberty - Phthalate contaminated-foodstuff episode in Taiwan. In May 2011, a major incident involving phthalates-contaminated foodstuffs occurred in Taiwan. Di-(2-ethylhexyl) phthalate (DEHP) was added to foodstuffs, mainly juice, jelly, tea, sports drink, and dietary supplements. Concerns arose that normal pubertal development, especially reproductive hormone regulation in children, could be disrupted by DEHP

2017 PLoS ONE PubMed abstract

279. Contraception - combined hormonal methods

Contraception - combined hormonal methods Contraception - combined hormonal methods - NICE CKS Share Contraception - combined hormonal methods: Summary There are three types of combined hormonal contraceptives (CHCs): oral contraceptives, transdermal patch, and vaginal ring. CHCs act to inhibit ovulation: Ovulation is inhibited by the oestrogen and progestogen components which act on the hypothalamo-pituitary axis to reduce production of luteinizing hormone (LH) and follicle-stimulating hormone (...) ) which act on the hypothalamo-pituitary axis to reduce production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With no surge in LH and FSH to stimulate the ovaries, ovulation does not occur. CHCs also have contraceptive effects on cervical mucus and the endometrium. The oestrogen component of the CHC causes the endometrium to proliferate and grow. The progestogen component of the CHC prevents hyperplasia (excessive growth) of the endometrium by opposing the proliferative

2019 NICE Clinical Knowledge Summaries

280. Ovarian Stimulation for IVF/ICSI

INTRODUCTION 11 LIST OF ALL RECOMMENDATIONS 15 PART A: OVARIAN RESPONSE TESTING 26 1. Pre-stimulation management 26 KEY QUESTION: IS THE ASSESSMENT OF THE PREDICTED RESPONSE TO OVARIAN STIMULATION SUFFICIENTLY RELIABLE? 26 1.1 ANTRAL FOLLICLE COUNT (AFC) 26 1.2 ANTI-MÜLLERIAN HORMONE (AMH) 27 1.3 BASAL FOLLICLE STIMULATING HORMONE (FSH) 28 1.4 INHIBIN B 29 1.5 BASAL OESTRADIOL 30 1.6 AGE 31 1.7 BODY MASS INDEX (BMI) 31 1.8 OVERALL RECOMMENDATION 32 REFERENCES 33 2. Additional hormonal assessment (...) . 89 11.3 ULTRASOUND AND COMBINATION OF HORMONAL MEASUREMENTS 89 REFERENCES 89 12. Endometrial thickness 90 KEY QUESTION: DOES MONITORING OF ENDOMETRIAL THICKNESS AFFECT THE EFFICACY AND SAFETY? 90 REFERENCES 92 13. Criteria for triggering 93 KEY QUESTION: IS THE OUTCOME OF OVARIAN STIMULATION DEPENDENT ON THE CRITERIA FOR TRIGGERING? 93 13.1 FOLLICLE SIZE 93 13.2 OESTRADIOL LEVEL 94 13.3 OESTRADIOL/FOLLICLE RATIO 94 REFERENCES 95 14. Criteria for cycle cancellation 96 KEY QUESTION: WHICH CRITERIA

2019 European Society of Human Reproduction and Embryology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>